In preclinical exploration of MRT‐2359, researchers found that treatment of MRT‐2359 sensitive prostate cancer cell lines in vitro led to a loss of c‐MYC and, to a lesser extent, AR (including AR‐V7) proteins. The gene discussed is AR; the disease is prostate carcinoma.